Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Viewpoint - Surrozen, Inc. has granted stock option awards to new employees as an inducement for their acceptance of employment, reflecting the company's commitment to attracting talent in the biotechnology sector focused on severe eye diseases [1][2][3] Group 1: Stock Option Awards - Surrozen granted a total of 45,710 stock option awards to four recently hired non-executive employees [1] - The stock options were issued under Surrozen's 2025 Equity Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4) [2] - Each stock option allows the purchase of shares at a price of $12.32 per share, which was the closing price on September 2, 2025 [2] Group 2: Vesting Schedule - The stock options will vest over a four-year period, with 25% vesting on the first anniversary of the vesting commencement date based on the employee's hire date [3] - The remaining shares will vest ratably each month thereafter, contingent on the employee's continuous service [3] Group 3: Company Overview - Surrozen is a biotechnology company focused on developing tissue-specific antibodies to modulate the Wnt pathway, particularly in the field of ophthalmology [4] - The company's proprietary technologies aim to leverage the body's biological repair mechanisms to address severe diseases [4]